Atossa Genetics Inc (ATOS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.22 (-7.50%), Market cap $0.05B, 52-week low–high $0.56 ~ $6.17.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Financial statements, price targets, institutional (13F) holdings and related news for Atossa Genetics Inc are updated in real time on BlackAll Trade.
Atossa Genetics Inc trades at $2.22 (-7.50%). Real-time quotes and charts are available on BlackAll Trade.
Atossa Genetics Inc has a market cap of about $0.05B.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (